Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
Trends Mol Med. 2021 Jan;27(1):5-7. doi: 10.1016/j.molmed.2020.11.007. Epub 2020 Dec 5.
Despite increasing ability to understand and correct molecular derangements in disease, genomics and novel phenotypic assays are unevenly deployed in clinical practice. This has hampered translational research and our ability to identify clinically actionable subtypes of disease. Historic examples illustrate how the perspectives of stakeholders across the healthcare ecosystem can influence adoption of innovations in healthcare. Consideration of these factors, from discovery to implementation, can accelerate adoption of new molecular and digital phenotypes in a 'learning' healthcare ecosystem.
尽管在理解和纠正疾病中的分子紊乱方面的能力不断增强，但基因组学和新型表型检测在临床实践中的应用仍不均衡。这阻碍了转化研究和我们识别疾病临床可操作亚型的能力。历史实例说明了医疗保健生态系统中各个利益相关者的观点如何影响医疗保健创新的采用。从发现到实施，考虑这些因素可以加速新的分子和数字表型在“学习”医疗保健生态系统中的采用。
